{"doi":"10.1182/blood.2020008759","title":"Safety of CAR T-cell therapy in kidney transplant recipients","abstract":"Recipients of solid organ transplant are at increased risk to develop posttransplant lymphoproliferative disorder (PTLD). However, only 30% to 40% achieve a durable response. 2,3 Chimeric antigen receptor (CAR) T-cell therapy is a novel treatment with a substantial response (52% to 82%) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), 4,5 but its safety and efficacy in PTLD is unknown. Two CAR T-cell therapy products, axi-cel and tisagenlecleucel, are currently approved for r/r DLBCL and both are derived from autologous T cells. Because solid organ transplant recipients are on long-term immunosuppressive therapy to prevent allograft rejection, there is concern about the feasibility of generating an effective autologous CAR T-cell product. Here, we report the safety and efficacy of autologous CAR T-cell therapy in 3 patients with r/r DLBCL and kidney allograft who were treated with axi-cel in 2019 to 2020.","journal":"Blood","year":2020,"id":62206,"datarank":0.5983476069846413,"base_score":3.9889840465642745,"endowment":3.9889840465642745,"self_citation_contribution":0.5983476069846413,"citation_network_contribution":0.0,"self_endowment_contribution":0.5983476069846413,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":53,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9472,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":248726,"name":"Ranjit Nair","orcid":null,"position":1,"is_corresponding":false},{"id":328948,"name":"Swaminathan P. Iyer","orcid":"0000-0002-1646-813X","position":2,"is_corresponding":false},{"id":328949,"name":"Angelina Edwards","orcid":"0000-0001-6500-2072","position":3,"is_corresponding":false},{"id":11096,"name":"Sattva S. Neelapu","orcid":"0000-0003-1045-4914","position":4,"is_corresponding":false},{"id":328950,"name":"Raphaël Steiner","orcid":"0000-0003-3717-3629","position":5,"is_corresponding":false},{"id":328951,"name":"Sherry Adkins","orcid":"0000-0001-6290-904X","position":6,"is_corresponding":false},{"id":330253,"name":"Misha Hawkins","orcid":null,"position":7,"is_corresponding":false},{"id":330254,"name":"Neeraj Saini","orcid":null,"position":8,"is_corresponding":false},{"id":330255,"name":"Kartik Devashish","orcid":null,"position":9,"is_corresponding":false},{"id":247183,"name":"Paolo Strati","orcid":"0000-0002-7445-1459","position":10,"is_corresponding":false},{"id":328952,"name":"Sreedhar Mandayam","orcid":"0000-0001-9044-012X","position":11,"is_corresponding":false},{"id":247184,"name":"Sairah Ahmed","orcid":"0000-0001-7302-8299","position":12,"is_corresponding":false},{"id":328947,"name":"Omar Mamlouk","orcid":"0000-0002-1242-2740","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T21:10:11.612909Z","pmid":"33512386","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}